Navigation Links
Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
Date:5/23/2012

MONMOUTH JUNCTION, N.J., May 23, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease.

There have been very few clinical trials to support current NTM treatment recommendations, and no new drugs have been assessed in randomized trials for NTM lung disease in many years.   Additionally, NTM remains a significantly under-diagnosed disease.  TARGET-NTM represents an opportunity to make significant advancement in the awareness and treatment of this debilitating chronic illness, according to Kenneth N. Olivier, M.D., M.P.H., Principal Investigator of the study and staff pulmonologist in the Laboratory of Clinical Infectious Diseases at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

"Current treatment for NTM lung disease requires lengthy multi-drug regimens that can be poorly tolerated and have limited efficacy, especially in patients with severe disease or in those who have failed prior treatment attempts," said David E. Griffith, M.D., lead author of the American Thoracic Society's and the Infectious Disease Society of America's diagnosis and treatment guidelines for NTM, and Professor of Medicine at the University of Texas Health Science Center at Tyler. "If effective, ARIKACE has the potential to significantly impact the current NTM treatment paradigm."  Dr. Griffith, along with Richard J Wallace, M.D., Professor of Medicine and Microbiology, also at the University of Texas Health Science Center at Tyler, are Co-Principal Investigators for the study.

NTM Increasingly Prevalent

According to a
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Insmed Announces First Quarter 2012 Financial Results
2. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
3. Insmed to Host 2012 First Quarter Earnings Conference Call
4. Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
5. Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
6. Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication
7. Insmed Incorporated Provides Regulatory Update
8. Insmed to Present at Sixth Annual JMP Securities Healthcare Conference
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011
10. Insmeds ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
11. Insmed Announces First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Inc. (Vanda) (NASDAQ: VNDA ) today announced that ... of the Year by the Tech Council of ... 25 th Annual Tech Awards Celebration held in ... the leaders and innovators in the technology and life science ... regions. "We are deeply honored to receive ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. ... stage medical device company that develops and sells high ... of its rights offering.  In addition, the concurrent temporary ... warrants expired on May 17, 2013. Nephros ... million from the rights offering.   A portion of the ...
(Date:5/23/2013)... May 23, 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, ... companies, based on intellectual property developed and owned ... ,s foremost medical research center, today announced that ... significant funding from the Israeli Ministry of Industry ... to support product development and advance clinical trials. ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... EDISON, N.J., July 15, 2011 Crestor ... designed to lower "bad cholesterol". Both drugs are classified ... inhibiting HMG-CoA reductase. This group of drugs has had ... to Crestor and Zocor, touted as a "super statin" ...
... N.J., July 15, 2011 Janssen Pharmaceuticals, Inc. ... assets of its Ortho Dermatologics division in the ... for approximately $345 million in cash. The divestiture ... MICRO®, ERTACZO® and RENOVA®) sold in the U.S. ...
Cached Medicine Technology:Crestor and Zocor Drugs Linked to Muscle Degeneration, Rhabdomyolysis 2Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division 2
(Date:5/25/2013)... 2013 Dr. Farooq Ashraf, founder of ... Dubai, has announced his practice’s adoption of The iFS ... FDA-cleared femtosecond laser proven with more than 10 years ... of LASIK. , “We are happy to announce that ... at our Dubai LASIK practice,” Ashraf said Thursday. “We ...
(Date:5/25/2013)... Acuity Games ’ innovative brain games have ... Word Hunt is available today, expanding it beyond its ... 2, Sudoku and Matchematics will roll out over the next ... lifetime brain fitness measurement have been re-optimized for the iPhone's ... brain fitness measurement in your pocket. What could be ...
(Date:5/25/2013)... Los Angeles, CA (PRWEB) May 25, 2013 ... will grow at an average annual rate of 28.7% ... growth of 17.9% in 2013. From 2002 and 2008, no ... analyst Kevin Culbert, causing relatively modest growth during that period. ... (FDA) has approved six new products. This factor contributed to ...
(Date:5/25/2013)... May 25, 2013 For college ... finals week. Increasingly, they are turning to prescription ... and study. For more on this, go to ... treatment facility, warns that students who pick up ... at risk for developing a physical and psychological ...
(Date:5/25/2013)... Ayurveda is the traditional medicine of ... of life". While a medical science, its scope enters into ... Its fundamental philosophy is that disease is the end result ... that in order to re-establish optimal health, we must discover ... a life style which brings us back into harmony. , ...
Breaking Medicine News(10 mins):Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Acuity Games Apps Come to the iPhone 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2
... test, based on gene expression and predicting the tumours that ... was presented today at the 3rd International Conference on innovative ... Dr Robert Takes, from the Radboud University Nijmegen Medical Centre, ... of oral or oropharyngeal cancer. The study was jointly led ...
... of the factors reported by those who say they are unhappy ... its kind, published in the launch issue of the new online ... challenge the perception that these patients can no longer enjoy quality ... the authors. The research team quizzed 168 members of the ...
... 24 (HealthDay News) -- An analysis of proteins in spinal ... with chronic fatigue syndrome, a new study reports. It ... involve the central nervous system and that protein abnormalities in ... conditions, said the research team, which was led by Dr. ...
... microbiological equilibrium in the female genital tract can lead ... Deutsches rzteblatt International ( Dtsch Arztebl Int ... Bitzer investigates a method of screening for such changes., ... preterm deliveries. To avoid these, in a model project ...
... . , When the family doctor is a woman, patients ... their health problem, especially when it is a family health problem ... family doctor "listening to them, keeping them informed and considering their ... conclusion drawn of a study recently conducted by Ana Delgado, ...
... Feb. 24 (HealthDay News) -- Most "locked-in syndrome" patients -- ... be happy, according to a new study. People with ... except through eye movements or blinking. Patients with the condition ... surveyed 91 locked-in syndrome patients in France about their medical ...
Cached Medicine News:Health News:Gene expression to distinguish metastasizing from non-metastasizing head and neck cancers 2Health News:Most 'locked-in syndrome' patients say they are happy 2Health News:Spinal Fluid May Hold Clues to Lyme Disease, Chronic Fatigue Syndrome 2Health News:When the doctor is a woman, patients expect them to be involved in decision making 2Health News:Most 'Locked-In Syndrome' Patients Happy, Survey Finds 2
This is long known for its purity and mildness, Castile Soap is also an effective cleaning agent that is used in a variety of applications. It rinses clean while leaving the skin soft and healthy....
Upon application to intact skin, Skin-Prep* protective wipes forms a protective film that prepares the skin for the attachment of drainage tubes, external catheters, adhesive dressings and can be...
Triad Plus Sterile Isopropyl Alcohol 70% USP Prep Pads are medium size. Each package is terminally sterilized, ensuring the safest possible product....
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: